[Stimulation of endogenous secretion of the growth hormone. Today in diagnosis, tomorrow in therapy?].
Lebl. J J; Pechová. M M
Key Findings
- Sermorelin raised GH above 14 mIU/L in 18 of 31 children (≈58%)
- Higher response rate in children with isolated GHD versus multiple pituitary deficiencies
- A non‑significant trend toward better response in children born breech
Practical Outcomes
- For biohackers, the data suggest that GHRH‑based peptides might eventually help trigger natural GH release, but current evidence is limited to pediatric patients and not a ready‑to‑use protocol for adults. More adult‑focused trials are needed before applying sermorelin or similar compounds for longevity or performance.
Summary
The study tested sermorelin, a growth‑hormone‑releasing peptide, in kids with growth‑hormone deficiency and found it boosted their own GH levels in about half of the cases, especially in those with isolated deficiency. This hints that stimulating the body’s own GH could someday replace daily GH shots, but the work is in children and not yet ready for adult self‑experimenters.
Abstract
Treatment with growth hormone (GH) restores the natural growth rate in children with growth hormone deficiency (GHD). This is, however, achieved only after daily injections extending over many years and therefore daily short-term hypersomatotropinaemia. Stimulation of endogenous secretion of GH e.g. by oral administration of growth hormone-releasing peptide (GHRP) may help in future to eliminate these adverse aspects. This treatment could be beneficial in patients with a stimulable endogenous GH secretion. In order to find potential candidates for spontaneous secretion of GH the authors examined, using a test with sermoreline (GHRH1-29NH2), 31 children (21 boys) aged 5.8-16.5 years suffering from idiopathic (GHD), previously treated by daily GH injections. GH rose after stimulation with sermoreline to more than 14 mIU/l in 18/31 children (responders). The ratio of "responders" was higher in the sub-group of children with isolated GHD, as compared with multiple pituitary deficiency (p = 0.05) and insignificantly higher in the sub-group of children born by breech delivery (p = 0.13). More than half the children treated nowadays with GH could profit in future from the method of spontaneous GH secretions. The success of this procedure is more likely in children with isolated GHD and in breech delivered children.
Study Information
pubmed
1995
1995-06-14T00:00:00.000Z